Everolimus-induced somatostatin receptor overexpression in a rectal neuroendocrine tumor patient may promote somatostatin receptor-guided radionuclide therapy (peptide receptor radiotherapy) as an additional treatment option.

Mileva, Magdalena; Wimana, Zéna; Flamen, Patrick; Karfis, Ioannis

Mileva, Magdalena; Wimana, Zéna; Flamen, Patrick; Karfis, Ioannis.

Afiliação

Mileva M; Department of Nuclear Medicine, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.
Wimana Z; Department of Nuclear Medicine, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.
Flamen P; Department of Nuclear Medicine, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.
Karfis I; Department of Nuclear Medicine, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.

World J Nucl Med ; 20(3): 316-318, 2021.

Article em En | MEDLINE | ID: mdl-34703403

Palavras-chave

Everolimus; peptide receptor radiotherapy; somatostatin receptor; up-regulation

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: World J Nucl Med Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Bélgica

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google